cemiplimab (Libtayo)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 3 mg/kg every 2 weeks

Adverse effects

Mechanism of action

  • inhibits PD-1 pathway

More general terms

References

  1. Kuznar W with expert critique by Klil-Drori AJ Cemiplimab Gains Approval for Advanced Squamous Cell Carcinoma. Durable responses with first systemic agent for this group of patients. MedPage Today. ASCO Reading Room 10.27.2018. https://www.medpagetoday.com/reading-room/asco/skin-cancer/75935
    Migden MR, Rischin D, Schmults CD et al PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 2018; 379:341-351 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29863979 https://www.nejm.org/doi/full/10.1056/NEJMoa1805131
  2. 2.0 2.1 Marin-Acevedo JA, Chirila RM, Dronca RS. Immune Checkpoint Inhibitor Toxicities. Mayo Clinic Proc. July 2019. 94(7):1321-1329 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31272574
  3. Bankhead C First Immunotherapy Approved for Basal Cell Carcinoma - Objective responses in 27% of previously treated patients who received cemiplimab. MedPage Today February 10, 2021 https://www.medpagetoday.com/hematologyoncology/skincancer/91145